Featured Partners

Accenture Names Domingo Mirón Group Chief Executive — Financial Services, Succeeding Richard Lumb

Accenture has appointed Domingo Mirón as group chief executive — Financial Services, effective Sept. 1, 2019. He succeeds Richard Lumb, who will retire from the company on Aug. 31, 2019. Mirón currently serves as group operating officer for Accenture’s Financial Services operating group, with responsibility for executing the operating group’s…

GNS Healthcare Raises $23M Led By Cigna Ventures

Originally Posted on Cigna.com GNS Healthcare (GNS), a leading precision medicine company, today announced a $23 million Series D fundraising round, led by Cigna Ventures, a strategic corporate venture capital partner and a wholly-owned indirect subsidiary of Cigna Corporation. Joining the Cigna Ventures-led funding round were Amgen Ventures, Celgene, Echo…

Johnson & Johnson: XARELTO Helps Protect Pediatric Patients from Blood Clots in Late-Breaking Phase 3 EINSTEIN-Jr Study

Originally posted on JNJ.com The Janssen Pharmaceutical Companies of Johnson & Johnson announced today new results from the Phase 3 EINSTEIN-Jr study, showing pediatric patients (aged birth to 17 years) treated with XARELTO® (rivaroxaban) had a similar low risk of recurrent venous thromboembolism (VTE) – or blood clots – and similar…

XARELTO® (rivaroxaban) Helps Protect Pediatric Patients from Blood Clots in Late-Breaking Phase 3 EINSTEIN-Jr Study

Originally posted on Johnson & Johnson The Janssen Pharmaceutical Companies of Johnson & Johnson announced today new results from the Phase 3 EINSTEIN-Jr study, showing pediatric patients (aged birth to 17 years) treated with XARELTO® (rivaroxaban) had a similar low risk of recurrent venous thromboembolism (VTE) – or blood clots –…